Published in Nat Genet on September 12, 2004
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest (2012) 3.09
Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol (2009) 2.65
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood (2008) 2.10
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood (2008) 1.95
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia (2012) 1.93
ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal (2010) 1.91
WT1 mutations in T-ALL. Blood (2009) 1.75
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 1.68
Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res (2010) 1.62
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev (2010) 1.54
A sequence-based survey of the complex structural organization of tumor genomes. Genome Biol (2008) 1.45
Nuclear pore proteins and cancer. Semin Cell Dev Biol (2009) 1.44
Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet (2013) 1.29
Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica (2016) 1.23
Aberrant cytokine signaling in leukemia. Oncogene (2007) 1.20
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood (2015) 1.19
The role of nuclear pores in gene regulation, development and disease. EMBO Rep (2009) 1.17
Defining the role of essential genes in human disease. PLoS One (2011) 1.17
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood (2009) 1.16
Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood (2013) 1.13
Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther (2012) 1.09
Role of the nuclear envelope in genome organization and gene expression. Wiley Interdiscip Rev Syst Biol Med (2011) 1.04
Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer (2009) 1.04
T-cell acute lymphoblastic leukemia. Haematologica (2009) 1.04
Abl tyrosine kinases in T-cell signaling. Immunol Rev (2009) 1.04
Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. Haematologica (2010) 1.04
Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol (2009) 1.02
TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. Haematologica (2009) 1.01
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica (2010) 1.01
Crystal structure of the N-terminal domain of the human protooncogene Nup214/CAN. Proc Natl Acad Sci U S A (2007) 1.00
The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00
Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults. Haematologica (2010) 0.98
TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J Haematol (2006) 0.96
Genomic profiling of B-progenitor acute lymphoblastic leukemia. Best Pract Res Clin Haematol (2011) 0.95
SET-CAN, the product of the t(9;9) in acute undifferentiated leukemia, causes expansion of early hematopoietic progenitors and hyperproliferation of stomach mucosa in transgenic mice. Am J Pathol (2007) 0.95
The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol (2013) 0.94
A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica (2009) 0.94
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia (2008) 0.93
Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 0.93
Molecular cytogenetics in haematological malignancy: current technology and future prospects. Chromosoma (2005) 0.92
In vivo reinsertion of excised episomes by the V(D)J recombinase: a potential threat to genomic stability. PLoS Biol (2007) 0.92
Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer (2012) 0.90
c-MYC-induced genomic instability. Cold Spring Harb Perspect Med (2014) 0.89
Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy. Cancer Microenviron (2012) 0.88
Nuclear transport of galectin-3 and its therapeutic implications. Semin Cancer Biol (2014) 0.87
Alterations in DNA replication and histone levels promote histone gene amplification in Saccharomyces cerevisiae. Genetics (2010) 0.86
NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica (2013) 0.85
In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML. PLoS One (2010) 0.85
Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia. Haematologica (2009) 0.82
Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia. Leukemia (2015) 0.81
The new nucleoporin: regulator of transcriptional repression and beyond. Nucleus (2012) 0.80
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget (2015) 0.80
NUP214 fusion genes in acute leukemia (Review). Oncol Lett (2014) 0.79
The genetics and molecular biology of T-ALL. Blood (2017) 0.78
Genome Fusion Detection: a novel method to detect fusion genes from SNP-array data. Bioinformatics (2013) 0.78
Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet (2010) 0.78
NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. Haematologica (2015) 0.77
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood (2016) 0.77
Identification of interconnected markers for T-cell acute lymphoblastic leukemia. Biomed Res Int (2013) 0.77
Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy. Leukemia (2013) 0.76
Episomal amplification of MYCN in a case of medulloblastoma. Virchows Arch (2008) 0.76
Amplification of NOTCH1 and ABL1 gene loci is a frequent aberration in enteropathy-type T-cell lymphoma. Virchows Arch (2005) 0.76
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet (2017) 0.75
Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Oncotarget (2016) 0.75
Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia. Curr Cancer Drug Targets (2013) 0.75
Genetic aberrations in childhood acute lymphoblastic leukaemia: application of high-density single nucleotide polymorphism array. Malays J Med Sci (2010) 0.75
Genetic technologies in cancer investigation - applications in aggresive lymphoid malignancies. Maedica (Buchar) (2012) 0.75
NF-κB in T-cell Acute Lymphoblastic Leukemia: Oncogenic Functions in Leukemic and in Microenvironmental Cells. Cancers (Basel) (2010) 0.75
RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia. Case Rep Hematol (2015) 0.75
The DN2 Myeloid-T (DN2mt) Progenitor is a Target Cell for Leukemic Transformation by the TLX1 Oncogene. J Bone Marrow Res (2013) 0.75
GFusion: an Effective Algorithm to Identify Fusion Genes from Cancer RNA-Seq Data. Sci Rep (2017) 0.75
Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: A case report. Exp Ther Med (2017) 0.75
Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci (2017) 0.75
Chronic sun exposure-related fusion oncogenes EGFR-PPARGC1A in cutaneous squamous cell carcinoma. Sci Rep (2017) 0.75
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Myb-related Schizosaccharomyces pombe cdc5p is structurally and functionally conserved in eukaryotes. Mol Cell Biol (1998) 10.34
The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell (1985) 10.17
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2005) 7.03
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med (2000) 5.04
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 4.64
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med (1994) 4.46
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell (1999) 4.04
Human aminopeptidase N is a receptor for human coronavirus 229E. Nature (1992) 3.91
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology (2005) 3.90
Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet (2005) 3.87
Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome. J Med Genet (2009) 3.87
Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports. J Med Genet (2006) 3.70
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol (2008) 3.47
T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol (2008) 3.45
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1995) 3.38
Recurrent reciprocal deletions and duplications of 16p13.11: the deletion is a risk factor for MR/MCA while the duplication may be a rare benign variant. J Med Genet (2008) 3.35
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia (2009) 3.23
Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest (1977) 3.14
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol (2005) 2.97
Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol (2002) 2.86
Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood (1997) 2.75
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood (1996) 2.73
Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol (2000) 2.71
Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet (2001) 2.70
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell (2003) 2.70
Myelopoiesis in the zebrafish, Danio rerio. Blood (2001) 2.67
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med (1992) 2.64
Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood (1995) 2.59
Oral rehydration in infantile diarrhoea. Controlled trial of a low sodium glucose electrolyte solution. Arch Dis Child (1978) 2.58
The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia (2006) 2.57
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet (2007) 2.55
Small supernumerary marker chromosomes--progress towards a genotype-phenotype correlation. Cytogenet Genome Res (2006) 2.52
SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell (1999) 2.52
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med (2008) 2.49
Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A (1998) 2.46
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell (2000) 2.41
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst (1995) 2.35
The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials. Genes Dev (1991) 2.34
Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood (2000) 2.30
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol (2000) 2.30
Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res (1993) 2.24
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res (2006) 2.23
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol (2000) 2.21
Cryptic deletions are a common finding in "balanced" reciprocal and complex chromosome rearrangements: a study of 59 patients. J Med Genet (2007) 2.21
PHF6 mutations in adult acute myeloid leukemia. Leukemia (2010) 2.20
Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol (1999) 2.20
Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer (1999) 2.20
Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science (1992) 2.19
Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood (2003) 2.13
Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion. Nat Genet (2006) 2.11
Cell surface expression of v-fms-coded glycoproteins is required for transformation. Mol Cell Biol (1984) 2.09
Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med (1984) 2.09
False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia (2003) 2.09
Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J (1997) 2.06
Molecular karyotyping: array CGH quality criteria for constitutional genetic diagnosis. J Histochem Cytochem (2005) 2.05
Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol (2001) 2.03
Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood (1996) 2.02
[Non-cardiogenic acute edema of the lung after recurrent air venous embolism]. Rev Esp Anestesiol Reanim (2001) 2.02
New chromosomal translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leukemia. Cell (1984) 1.99
Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics (1992) 1.99
MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene (1998) 1.99
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A (1996) 1.98
A case of TdT-positive B-cell acute lymphoblastic leukemia. Am J Clin Pathol (1986) 1.97
The Pearson product-moment correlation coefficient is better suited for identification of DNA fingerprint profiles than band matching algorithms. Electrophoresis (1993) 1.97
Comparison of gas exchange after lung resection with a Boussignac CPAP or Venturi mask. Br J Anaesth (2014) 1.97
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol (1991) 1.94
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
Control of blood glucose and diabetic vascular disease. N Engl J Med (1977) 1.92